MENLO PARK, Calif., Sept. 9, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage ophthalmic medical device company, today announced further favorable results of a trial evaluating a single treatment of TearCare® for the treatment of signs and symptoms of dry eye disease in patients with meibomian gland dysfunction. TearCare is currently marketed for the application of localized heat to the eyelids for conditions such as meibomian gland dysfunction, dry eye, or blepharitis.
Data from the study were presented at the Women in Ophthalmology (WIO) 2020 Virtual Summer. The Symposium is uniquely curated to offer "the best of the best" content in all subjects important to women ophthalmologists, including dry eye disease, which disproportionately impacts female patients.
The OLYMPIA study was designed to evaluate the safety and effectiveness of a single TearCare procedure compared to a single LipiFlow® procedure (Johnson & Johnson, Jacksonville, Fla.) in treating the signs and symptoms of dry eye disease. OLYMPIA was a prospective, randomized, multicenter trial that enrolled 235 dry eye patients at 10 U.S. sites. All the patients enrolled in the study had moderate to severe stage of dry eye disease associated with meibomian gland dysfunction. Seventy percent of enrolled patients were female.
Results from the OLYMPIA study in the subset of female subjects were presented at the Symposium by Jennifer Loh, M.D., practicing ophthalmologist at Loh Ophthalmology in Miami. In the subset of female subjects, a greater proportion of female TearCare patients experienced meaningful symptomatic relief compared to female LipiFlow patients, as measured by an improvement from baseline in ocular surface disease index (OSDI) score at one month. In the study, 76% of female subjects receiving TearCare improved by at least one OSDI severity category at one month, as compared to 56% of LipiFlow female patients. Similarly, 90% of female subjects receiving TearCare were observed to have clinically meaningful reductions (10.4 point reduction in severe cases and 7.3 point reduction in moderate cases) in OSDI scores from baseline, as compared to 79% of female subjects receiving LipiFlow.
"We are proud to have Dr. Loh present these findings at the WIO Symposium, as we continue to evaluate TearCare for the treatment of dry eye disease," said Paul Badawi, Chief Executive Officer of Sight Sciences. "We believe the OLYMPIA clinical results support the physiologic thesis behind the TearCare procedure for meibomian gland dysfunction, the leading cause of dry eye disease."
The results of the OLYMPIA study show statistically significant and clinically meaningful improvement in the primary signs of dry eye at two weeks that lasted through the duration of the study. Subjects receiving TearCare were observed to have increased tear break-up time (TBUT) by 2.7 ± 3.7 at two weeks and by 3.0 ± 4.2 seconds at one month (both p < 0.0001), and meibomian gland secretion (MGS) score by 10.5 ± 10.9 at two weeks and by 11.2 ± 11.1 units at one month (both p < 0.0001) compared with baseline. Subjects receiving LipiFlow were also observed to have significantly increased TBUT and MGS score at two weeks and one month compared with baseline (all p < 0.0001). The improvements in signs for TearCare patients was numerically better compared to LipiFlow patients.
The results also show statistically significant and clinically meaningful improvement in symptoms measured as patient reported outcomes {OSDI, Symptom Assessment Questionnaire in Dry Eye (SANDE) and Eye Dryness Score (EDS)} at one month. Subjects receiving TearCare reported mean reductions of 27.6 ± 20.6, 38.2 ± 31.0 and 35.4 ± 34.1 respectively in OSDI, SANDE and EDS scores from baseline; all p < 0.0001. Subjects in the LipiFlow group reported mean reductions of 23.4 ± 17.7, 39.4 ± 25.9 and 34.8 ± 26.9 respectively in OSDI, SANDE and EDS scores from baseline; all p < 0.0001. TearCare subjects exhibited better symptomatic relief evidenced by requiring 22% less lubricant drops as a rescue therapy than LipiFlow subjects throughout the study period of one month (p<0.01). Adverse events in OLYMPIA (seven in the TearCare group and eight in the LipiFlow group) were transient, minor and resolved without requiring any further treatment.
Initial results from the OLYMPIA study were presented in May 2020 at the American Society of Cataract Refractive Surgery (ASCRS) Virtual Annual Meeting by Dr. Loh.
About Sight Sciences
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered ophthalmic products. The company's surgical product portfolio features the OMNI® Surgical System, a dually-indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm's canal, and collector channels) with a single device and single corneal incision.
The company's non-surgical product portfolio consists of TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed for the application of localized heat, which may be used to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea.
About TearCare
TearCare is the world's first wearable and intelligent eyelid technology for the application of localized heat to the eyelids. Through a combination of proprietary eyelid innovations including wearability, total tarsal conformance, blink assistance, and software-sensor controlled thermal optimization, TearCare safely, consistently, and non-invasively achieves and maintains the elevated tarsal conjunctival temperatures required to melt gland obstructions, permitting clearance of the critical oil-producing function of the meibomian glands within the eyelid that help to produce a healthy tear film.
TearCare is currently indicated for the application of localized heat when the current medical community recommends the application of a warm compress to the eyelids. Such applications would include Meibomian Gland Dysfunction (MGD), Dry Eye, or Blepharitis.
For more information, please visit sightsciences.com
TearCare® and OMNI® are registered trademarks of Sight Sciences.
© 2020 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
SOURCE Sight Sciences, Inc.
